Beyond PLLA Fillers: Siyuan Medical Pioneers Biomimetic Materials to Illuminate the Regenerative Aesthetics Industry

2021 was regarded by the industry as the inaugural year of regenerative medical aesthetics. The broad prospects of material innovation attracted enthusiastic capital inflows, and Nanjing Siyuan Medical Technology Co., Ltd. further expanded its portfolio of aesthetic medicine products based on biomimetic materials, thereby repeatedly gaining favor from investors.

Among upstream companies in the medical aesthetics industry, Siyuan Medical stands out as a unique entity. Leveraging its two core technology platforms—polycarbonate technology and hydrogel cross-linking technology—the company has successively developed a range of medical-grade polymer materials, including the currently popular “baby face” injections (poly-L-lactic acid fillers) in the medical aesthetics market. However, the founding team did not rest on these achievements; with their keen market insight, they had alreadyTurning its attention to the currently underexplored field of biomimetic materials.

What considerations drove the founding team of Siyuan Medical to strategically position itself in a diverse portfolio of new materials and products for regenerative medical aesthetics? What future direction do they firmly believe the medical aesthetics market is heading toward, and where do their strategic advantages lie? Recently, VCBeat held an exclusive dialogue with the founding team of Siyuan Medical.

VCBeat:In light of the current state of the medical aesthetics industry, where do you see the future direction of the market? How will Nanjing Siyuan Medical Technology Co., Ltd. strategize its layout?

Founder and CEO Feng Zhugang:“The era of using a single product or material class for full-face treatments has passed. The future of medical aesthetics belongs to innovations in both materials and their applications; our strategic focus on biomimetic materials positions us as a unique player in the industry.”

Since its inception, Siyuan Medical has collaborated with numerous universities, research institutions, and clinicians to jointly explore how to strategically position itself through the R&D and introduction of new materials.Comprehensive Product Pipeline Covering the Entire Face and All Anatomical Layers. In addition to basic products such as skin boosters and collagen-stimulating injections, the companyPrioritize the development and application of biomimetic materials, to better leverage the interaction between the product and the patient’s body to achieve optimal minimally invasive aesthetic outcomes.

Why Is the One-Size-Fits-All Approach of Using a Single Product or Material Class for Full-Face Treatment No Longer Viable?This is because different materials have varying degradation cycles, and differences in their physical properties, softness/hardness, and microstructure all influence the design direction for injection depth and aesthetic outcomes.For instance, firmer materials are suitable for deep injection and localized contouring, whereas softer materials are more appropriate for superficial injection to treat fine lines or for large-area volumizing.

Furthermore, the application sites of the products should align with the characteristics of human anatomical structures. For instance, due to the favorable tissue dispersion properties of PLLA biostimulators (commonly known as "baby face injections"), newly generated collagen is better supported by the underlying bone structure, resulting in a more natural and voluminous appearance. This makes them particularly suitable for large-area anti-aging filler treatments in the mid-face, thereby achieving superior outcomes. Therefore, based on an analysis of human anatomical features, we have matched each product with its optimal application method.

Secondly,We also considered the differences in mechanisms of action among various medical aesthetic materials and products., to meet the demands of today's aesthetic seekers and increasingly refined application scenarios, research and modificationBiomimetic Materialsthe original physical properties, allowing the productIt offers the dual benefits of immediate filling and induction of tissue regeneration.This is ourPositioning Biomimetic Materials as a Strategic Initiativean important consideration.

Develop products based on refined demand, enrich material offerings, and build high barriers across multiple dimensions. As the future aesthetic medicine market is bound to diversify, we must ensure we always have strategic options at our disposal.

VCBeat:The market for poly-L-lactic acid (PLLA) dermal fillers, commonly known as "baby face injections," is currently experiencing significant growth. Nanjing Siyuan Medical Technology Co., Ltd.'s comparable product has already entered the clinical trial enrollment phase. How do you view this new material?

Co-founder and Head of R&D, Zhang Jianjun:The ultimate market demand lies in the combination of immediate results and long-lasting, natural-looking effects. The advantages of immunostimulatory materials such as poly-L-lactic acid (PLLA) fillers are also their limitations. We cannot rest on our laurels; instead, we must continuously develop other novel materials and strive to identify the optimal solutions.

Immunostimulatory materials stimulate immune cells to release cytokines, thereby inducing fibroblast proliferation and accelerating collagen secretion. This results in natural-looking outcomes that can last for more than two years. However, the limitations of immunostimulatory materials are also evident. Their tissue-filling effect relies on endogenous collagen regeneration, a process that takes 2–3 months. Consequently, they do not provide immediate results comparable to those of physical fillers and fail to meet aesthetic patients’ demand for “instant beautification.”

To crack this “unsolvable” problem, Siyuan Medical has focused its strategic layout on biomimetic materials.Biomimetic materials combine the advantages of physical fillers and immunostimulatory agents, enabling safer "instant aesthetic enhancement" while transforming this immediate effect into long-lasting, "natural-looking beauty." Once launched on the market, they are certain to attract widespread attention.

VCBeat:From a market perspective, what do you see as the strategic advantages of Nanjing Siyuan Medical Technology Co., Ltd.'s layout?

Co-founder and Chief Marketing Officer, Sun Lili:Deploying comprehensive, full-face, multi-layered treatment strategies that balance immediate results with long-term maintenance, we closely align with aesthetic seekers’ demand for ideal products. This approach strengthens the integration of medicine and aesthetics, enabling us to seize present opportunities while securing future success.

Currently, the mainstream regenerative materials in the medical aesthetics market are led by poly-L-lactic acid (PLLA) and polycaprolactone (PCL). Both are immunostimulatory materials that primarily act on the dermal and subcutaneous layers, with the nasolabial folds as the primary treatment area.

As the demand for anti-aging treatments among aesthetic seekers continues to expand, the desire for superior solutions will drive the development of more refined, targeted regenerative medical aesthetics products. More regenerative materials will gradually transition from laboratories and clinical settings to the aesthetic medicine sector, with an increasing number of indications gaining regulatory approval, thereby continuously enriching the portfolio of injectable aesthetic products and optimizing their efficacy.

Biomimetic materials, akin to a rising star, will lead the development of the medical aesthetics market and drive the continuous upgrading of the industry.

Overall, Siyuan Medical’s strategic layout aligns with market demands, leveraging immunostimulatory materials to capture current opportunities while prioritizing biomimetic materials to secure future competitiveness.The company’s foundational products, such as skin boosters and collagen-stimulating injections, have entered the clinical trial enrollment phase. Meanwhile, production, testing, and clinical activities for its key biomimetic product portfolio are proceeding in an orderly manner.

In the future, Nanjing Siyuan Medical Technology Co., Ltd. will continue to stay closely attuned to aesthetic seekers, deeply explore market demands, address industry pain points, and consistently deliver high-quality products to meet evolving customer needs.

Postscript:

Through our dialogue with the founding team of Siyuan Medical, we have come to recognize that “baby-face injections” are merely one material within the broader field of regenerative aesthetic medicine. Siyuan Medical’s forward-looking strategic layout in biomimetic materials has shattered our conventional perceptions, revealing the boundless potential for development in regenerative aesthetics. We believe that this visionary and innovative company is poised to become a beacon illuminating the industry’s future.